Purchase Order HHSN261201000184P

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,987.00 on August 31, 2017, with final completion scheduled for March 19, 2018. Performance takes place in Bethesda, Maryland. The order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio for federal genomic research applications. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $4,066.13 on December 4, 2017, with a completion date of January 31, 2018. The order covers a maintenance agreement for Illumina sequencing equipment. Work is performed in San Diego, California. The purchase order carries firm fixed price terms and no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc., valued at $10,697.76, on November 15, 2017, for firm fixed price delivery by November 30, 2017. Place of performance is Bethesda, Maryland. The order procures sequencing reagents, consumables, or related bioinformatics products aligned with Illumina's core portfolio of DNA and RNA sequencing instruments and supplies.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on September 7, 2017, with a ceiling value of $6,700.18.</p> <p>Place of performance is Bethesda, MD 20892. The order has a firm fixed-price structure and an ultimate completion date of October 8, 2017. The delivery order calls for genetic sequencing equipment, reagents, consumables, or bioinformatics software consistent with Illumina's portfolio of DNA and RNA sequencing instruments and analytical tools.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $26,357.76 on June 29, 2017, with an ultimate completion date of June 30, 2018. Work is performed in San Diego, California. The order covers sequencing reagents, consumables, or related biotechnology products and services. No set-aside category applied to this procurement.</p>

<p>The National Cancer Institute issued a purchase order to Illumina, Inc. valued at $14,380.62 on July 9, 2019, under a bridge agreement with an ultimate completion date of February 26, 2020. No set-aside was used. Work is performed in San Diego, California. The order procures DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software on a firm fixed price basis.</p>

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on August 17, 2018, for genetic sequencing and genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD. The order has a firm fixed-price pricing structure and an ultimate completion date of September 15, 2018. Illumina manufactures advanced DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software supporting genomic research across federal agencies.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,198.50 in scientific equipment, effective February 9, 2021, with completion targeted March 31, 2021. Performance occurs in San Diego, California. The order is firm fixed-price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $8,616.96 on September 20, 2017, for biological kits. Place of performance is San Diego, California. The order is firm fixed price with an ultimate completion date of October 20, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>